文献速递前列腺癌

集群化给药显著减少卡巴他赛浪费并降低转移性去势抵抗性前列腺癌治疗成本

Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-10-21

卡巴他赛以60 mg单剂量瓶包装,远高于平均处方剂量,造成大量药品浪费和成本增加。研究采用集群化策略,将计划接受卡巴他赛(20 mg/m2 每3周)的多名患者尽量安排在同一工作日治疗,并保存瓶内剩余药物供同日后续患者使用。3年内74例患者接受402次治疗,估计节省药品成本394 536加元(21.1%)。

要点

  • 集群化给药策略将卡巴他赛治疗安排在同一工作日,共享瓶内剩余药物。
  • 3年内74例患者402次治疗,估计节省药品成本394 536加元(21.1%)。
  • 该策略可减少药品浪费,降低患者、机构和相关方的经济负担。

核心结论

  • 集群化给药策略可显著减少卡巴他赛药品浪费并降低治疗成本。

研究设计与样本

  • 单中心实施成本节约的集群化策略,将计划接受卡巴他赛20 mg/m2 每3周的患者尽量安排在同一工作日治疗,保存瓶内剩余药物供同日后续患者使用。
  • 回顾性分析3年内74例患者接受的402次卡巴他赛治疗。
  • 比较集群化策略下实际使用药瓶数与假设每次治疗使用一瓶的估计成本,并计入赛诺菲-安万特提供的折扣激励。

主要发现

  • 67.4%的治疗日有多名患者接受治疗。
  • 同日安排3名患者可节省1瓶药物。
  • 估计总药品成本节省394 536加元(21.1%)。

关键数值与推荐

  • 卡巴他赛剂量为20 mg/m2 每3周。
  • 药品包装为60 mg单剂量瓶。
  • 3年内74例患者接受402次治疗。
  • 估计节省药品成本394 536加元(21.1%)。

临床怎么用

  • 在进一步安全性和有效性研究前,可考虑采用集群化给药策略以减少卡巴他赛药品浪费。
  • 类似策略可考虑用于其他肿瘤药物以降低药品浪费相关成本。

局限性

  • 需进一步研究评估该策略的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cabazitaxel is used to treat patients with metastatic castration-resistant prostate cancer progressing after docetaxel. It is prepackaged in 60 mg single-dose vials, a quantity much higher than the average prescribed dose, which leads to, substantial drug wastage (DW) and associated costs. To minimize DW we implemented a cost-saving, cohorting strategy where multiple patients scheduled to receive cabazitaxel (at a dose of 20mg/m2 every 3 wks) were cohorted and treated on a single weekday whenever possible. Excess drug from each vial was then saved and used for subsequent patients treated on the same day. The drug cost with cohorting was calculated from the actual number of vials used, and the drug cost without cohorting was estimated by assumingthat one vial was used per treatment. The cost of DW was determined based on the amount of drug that was discarded. All cost calculations also accounted for the discount incentives offered by Sanofi-Aventis. Over a 3-yr period, 74 patients received 402 treatments of cabazitaxel. Multiple patients were treated on 67.4% of the treatment days, and grouping of three patients on one day saved one vial. The estimated total drug cost saved was $394 536 CAD (21.1%). Pending further studies on safety and efficacy, this strategy could potentially be adopted to mitigate DW for cabazitaxel and similarly for other oncology drugs. This would significantly decrease the overall financial burden on patients, institutions, and stakeholders. PATIENT SUMMARY: Cabazitaxel chemotherapy is associated with substantial drug wastage and associated costs. By cohorting patients scheduled to receive cabazitaxel on a single weekday, the total drug cost was decreased by $394 536 CAD (21.1%) over a 3-yr period. Similar strategies could be considered to overcome the prohibitory costs associated with drug wastage for cabazitaxel and other cancer drugs.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Jiang DM, Fallah-Rad N, Lee R, et al. Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2020. PMID: 33461737. doi:10.1016/j.eururo.2020.09.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。